Aclarion Presents at the NIH HEAL Initiative Fall Meeting
BROOMFIELD, CO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan decision support tool will be presented at the 2023 Fall Meeting for the NIH HEAL Initiative BACPAC Research Program on November 1-2, 2023. Aclarion will be presenting Nociscan, the first, evidence-supported , SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan is being utilized in the two leading low back pain trials within the HEAL Initiative – comeBACK and BEST.
- The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research.
- The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH HEAL Initiative, is an effort to address the need for effective and personalized therapies for chronic low back pain (cLBP).
- Nociscan is being utilized in the two leading low back pain trials within the HEAL Initiative – comeBACK and BEST.
- Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S., and the NIH is addressing the opioid crisis through this initiative.